



**FOR PATIENTS AND CARE PARTNERS**



---

Please visit [www.briumvipatientsupport.com](http://www.briumvipatientsupport.com) or call **1-833-BRIUMVI** (**1-833-274-8684**) Monday through Friday, 8 AM to 8 PM EST to learn more.

**To learn more about BRIUMVI, visit [www.briumvi.com](http://www.briumvi.com).**

---

Please see **Important Safety Information on pages 8-10** and accompanying **full Prescribing Information**.

---

# Welcome to BRIUMVI Patient Support

---

BRIUMVI Patient Support offers a flexible program to support the treatment journey in a way that works best for you. Our program focuses on what matters most, including the following:



## Dedicated Case Manager

Who will serve as your single point of contact and support you throughout your treatment journey



## Insurance Support

Information to help you understand your insurance coverage and locate a nearby infusion center that accepts your insurance



## Financial Assistance

Options that may help assist you with the cost of BRIUMVI, including the BRIUMVI Copay Assistance Program where eligible patients may pay **as little as \$0 copay** per BRIUMVI treatment, as well as help with covering infusion-related costs\*

## Enroll now to get started with BRIUMVI Patient Support

To get started with BRIUMVI Patient Support, your provider will work with you to complete, sign, and submit a Start Form.

We have made the enrollment process quick and easy. For more information, go to [briumvipatientsupport.com](http://briumvipatientsupport.com) or call 1-833-BRIUMVI (1-833-274-8684). Case Managers are available Monday through Friday, 8 AM to 8 PM EST.

\*For commercially insured patients only. Other eligibility requirements apply. Visit [www.briumvicopayterms.com](http://www.briumvicopayterms.com) for full terms and conditions.

**Please see Important Safety Information on pages 8-10 and accompanying full Prescribing Information.**

# What to expect after enrollment

1



## Case Manager Assignment

Your dedicated Case Manager will reach out to explain what you can expect when enrolling in the program

2



## Insurance Coverage Determination

Your Case Manager will call your insurance company to gather coverage details for your prescribed medication, BRIUMVI

3



## Financial Assistance

Your Case Manager will help you understand if you may be eligible for financial assistance options

4



## Infusion Support

Your Case Manager will reach out to confirm your scheduled infusion date, help locate a nearby infusion center if needed, and continue to reach out via your preferred communication method throughout your treatment journey

Please see **Important Safety Information on pages 8-10** and accompanying **full Prescribing Information**.



# What to expect after enrollment (cont'd)



## Case Manager Assignment

After enrollment, you will be assigned a dedicated BRIUMVI Patient Support Case Manager who will reach out to you via your preferred communication method. Your Case Manager will help you get started on BRIUMVI and assist you throughout your entire treatment journey.

Once we receive your Start Form, you can expect a text message to continue with the enrollment process.\* An example of the messages you may receive is shown on the right.



## Insurance Coverage Determination

The next step is to determine your insurance coverage. Your Case Manager will conduct a review of your insurance and discuss with you:

- How your insurance may cover BRIUMVI
- If there are specific requirements needed to access BRIUMVI
- Your out-of-pocket (OOP) costs for BRIUMVI

\*Opted-in patients only with a valid mobile number.

**Please see Important Safety Information on pages 8-10 and accompanying full Prescribing Information.**



## Financial Assistance

Next, your Case Manager will review if you may be eligible for financial assistance options.

- If you have commercial health insurance (also referred to as private insurance that is often obtained through an employer), you may qualify for the **BRIUMVI Copay Assistance Program**\*

### Treatment costs:

- Eligible patients may pay as little as \$0 copay per BRIUMVI treatment up to the annual maximum of \$20,000

### Infusion and administration costs:

- Eligible patients' OOP costs may be covered up to \$550 for the first infusion and then up to \$350 per infusion thereafter
- If you do not have insurance or are underinsured and meet certain financial eligibility criteria, you may qualify for the **BRIUMVI Patient Assistance Program**. You can ask your Case Manager for more information about the BRIUMVI Patient Assistance Program
- If you are not eligible for any financial assistance, there are third-party charitable organizations that may be able to help†

\*For commercially insured patients only. Other eligibility requirements apply. Visit [www.briumvicopayterms.com](http://www.briumvicopayterms.com) for full terms and conditions.

†TG Therapeutics is not affiliated with these organizations. Each organization sets its own eligibility and application process and is independent from TG Therapeutics. TG Therapeutics makes no guarantee a patient will receive any type of assistance or that funding is available. Please contact each organization directly to obtain more information.

**Please see Important Safety Information on pages 8-10 and accompanying full Prescribing Information.**

## What to expect after enrollment (cont'd)




4

### Infusion Support

After your insurance coverage has been verified, your Case Manager will ensure that your infusion center has all the necessary information to schedule your appointment as soon as possible.

If your provider does not administer infusions in his or her office, your Case Manager can help you find a nearby infusion center that accepts your insurance.

Approximately 45 days prior to your scheduled infusion date, you will receive a notification from your Case Manager to confirm your infusion date and discuss any changes to your insurance plan, prescriber, and/or infusion center location.



Please see **Important Safety Information on pages 8-10** and accompanying **full Prescribing Information**.

# Care partner support

---

Care partners are a very important part of the treatment journey. If you are a care partner and are interested in support resources or connecting with other care partners, visit the helpful websites listed below.\* These organizations aid the friends or loved ones who support patients living with multiple sclerosis (MS).

## **Caregiving.com** **caregiving.com**

Features helpful media resources for people who support those living with MS. The website hosts podcasts, webinars, and virtual daily chats as well as blogs written by family caregivers.

## **Caregiveraction.org**

Offers learning resources and peer support to help improve the lives of those who care for people living with MS. Visit the website listed above or call 1-855-CARE-640.



\*TG Therapeutics is not affiliated with these independent organizations and does not recommend one organization over the other. Please note that the content of these websites is the sole responsibility of the website providers. TG Therapeutics does not control, review, edit, or influence this third-party content in any manner and makes no warranty as to the services offered by any organization listed here.

**Please see [Important Safety Information on pages 8-10](#) and accompanying [full Prescribing Information](#).**

# Important Safety Information

---

## Who should not receive BRIUMVI?

**Do not** receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

**Do not** receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

## What is the most important information I should know about BRIUMVI?

### BRIUMVI can cause serious side effects, including:

- **Infusion reactions:** Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:
  - fever
  - chills
  - headache
  - flu-like symptoms
  - fast heartbeat
  - hives
  - itchy skin
  - dizziness

- feeling faint
- swelling of tongue or throat
- trouble breathing
- wheezing
- nausea
- abdominal pain
- throat irritation
- redness of the face or skin

**These infusion reactions can happen over 24 hours after your infusion.** It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

- **Infection:**
  - Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.

**Please see accompanying full Prescribing Information.**



# Important Safety Information (cont'd)

- **Hepatitis B virus (HBV) reactivation:** Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
  - **Weakened immune system:** BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
  - **Progressive Multifocal Leukoencephalopathy (PML):** PML may happen with BRIUMVI. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
  - **Low immunoglobulins:** BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
- Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:**
- have or think you have an infection.
  - take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
  - have ever had hepatitis B or are a carrier of the hepatitis B virus.
  - have had a recent vaccination or are scheduled to receive any vaccinations.
  - **You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with BRIUMVI.** You **should not receive** ‘live’ or ‘live-attenuated’ vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
  - **When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with BRIUMVI.** If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.

Please see accompanying full Prescribing Information.

# Important Safety Information

---

- If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby's healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
- are pregnant, think that you might be pregnant, or plan to become pregnant. BRIUMVI may harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
- are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

## What are the possible side effects of BRIUMVI?

**The most common side effects of BRIUMVI include:**

- Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at **1-800-FDA-1088**. You may also report side effects to TG Therapeutics at **1-877-TGTXINC (1-877-848-9462)**.

For more important information, go to **[www.briumvi.com](http://www.briumvi.com)** or call 1-833-BRIUMVI (**1-833-274-8684**).

**Please see accompanying full Prescribing Information.**



Please see **Important Safety Information** on **pages 8-10** and accompanying full **Prescribing Information**.

 **briumvi**<sup>™</sup> **patient**  
ublituximab-xiiy 150 mg/6 mL  
injection for IV **support**



Please visit [www.briumvipatientsupport.com](http://www.briumvipatientsupport.com) or  
call 1-833-BRIUMVI (1-833-274-8684) to learn more about  
how BRIUMVI Patient Support can help.

—————  
**To learn more about BRIUMVI, please visit [www.briumvi.com](http://www.briumvi.com).**  
—————

**Please see Important Safety Information on pages 8-10 and accompanying  
full Prescribing Information.**

© 2023 TG Therapeutics, Inc. All rights reserved.  
BRIUMVI and its logos are trademarks of TG Therapeutics, Inc.  
US-BR-2300050 02/23

 **TG Therapeutics**